Ian Wark Research Institute, University of South Australia, Mawson Lakes, South Australia 5095, Australia.
Nanoscale. 2012 Feb 21;4(4):1220-30. doi: 10.1039/c1nr11273b. Epub 2011 Dec 9.
Lipid based colloids (e.g. emulsions and liposomes) are widely used as drug delivery systems, but often suffer from physical instabilities and non-ideal drug encapsulation and delivery performance. We review the application of engineered nanoparticle layers at the interface of lipid colloids to improve their performance as drug delivery systems. In addition we focus on the creation of novel hybrid nanomaterials from nanoparticle-lipid colloid assemblies and their drug delivery applications. Specifically, nanoparticle layers can be engineered to enhance the physical stability of submicron lipid emulsions and liposomes, satbilise encapsulated active ingredients against chemical degradation, control molecular transport and improve the dermal and oral delivery characteristics, i.e. increase absorption, bioavailability and facilitate targeted delivery. It is feasible that hybrid nanomaterials composed of nanoparticles and colloidal lipids are effective encapsulation and delivery systems for both poorly soluble drugs and biological drugs and may form the basis for the next generation of medicines. Additional pre-clinical research including specific animal model studies are required to advance the peptide/protein delivery systems, whereas the silica lipid hybrid systems have now entered human clinical trials for poorly soluble drugs.
脂质胶体（例如乳液和脂质体）被广泛用作药物传递系统，但常常存在物理不稳定性和不理想的药物包封和传递性能。我们综述了在脂质胶体界面应用工程化纳米颗粒层以改善其作为药物传递系统的性能。此外，我们还专注于从纳米颗粒-脂质胶体组装体中创建新型混合纳米材料及其药物传递应用。具体而言，纳米颗粒层可用于增强亚微米级脂质乳液和脂质体的物理稳定性，稳定封装的活性成分以防止化学降解，控制分子传输并改善经皮和口服传递特性，即增加吸收、生物利用度并促进靶向传递。由纳米颗粒和胶体脂质组成的混合纳米材料很可能是用于难溶性药物和生物药物的有效包封和传递系统，并可能成为下一代药物的基础。需要进行更多的临床前研究，包括特定的动物模型研究，以推进肽/蛋白质传递系统，而硅脂质混合系统现已进入用于难溶性药物的人体临床试验。
